Bradway Robert A 4

What Happened

• Robert A. Bradway, Amgen’s Chairman, CEO and President, exercised 119,782 stock options on 2026-03-04. The options had an exercise price of $156.35, representing an aggregate exercise cost of $18,727,916.
• To cover the option exercise price and tax withholding, the company withheld 84,285 shares valued at $379.27 each (total $31,966,772). After withholding, 35,497 shares were delivered to Bradway (119,782 − 84,285 = 35,497). The filing also shows a zero-dollar derivative settlement entry related to the exercise.
• Footnotes indicate these were non‑market (cashless) exercises of options expiring May 3, 2026 and that 2,414 Dividend Equivalents (DEs) are included in the shares.

Key Details

• Transaction date: March 4, 2026; Form filed March 6, 2026 (timely filing).
• Exercise price reported: $156.35; market price used for withholding/disposal: $379.27.
• Shares acquired via exercise: 119,782; shares withheld for taxes/exercise: 84,285; net shares delivered: 35,497 (≈ $13.46M at $379.27/share).
• Footnotes: non‑market cashless exercise; shares withheld to cover exercise price and tax withholding; includes 2,414 Dividend Equivalents tied to RSUs.
• Shares owned after the transaction: not specified in the provided excerpt.

Context

• This was an option exercise with company withholding (a common cashless exercise), not an open‑market sale or buy. Withholding of shares to cover taxes/exercise is routine and does not necessarily indicate a view on the company’s outlook.
• Transaction codes: M = option exercise/conversion; F = payment of exercise price/tax withholding.